PBRM1 and nonpapillary renal cell carcinoma: We have also shown that in ccRCC, including eosinophilic features related to loss of PBRM1 expression, significant clinical benefit was observed in the ICI therapy group compared to the TKI therapy group (p = 0.035) [14].